SCHEMBL4719786

SCHEMBL4719786

COc1cc2ncnc(-n3ncc4cc(Br)ccc43)c2cc1OC

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 5/20 0.59
ACHE P22303 3/20 0.54
BACE1 P56817 3/20 0.54
ATM Q13315 7/20 0.50
EGFR P00533 6/20 0.47
ERBB2 P04626 3/20 0.46
KDM4E B2RXH2 1/20 0.46
GAK O14976 1/20 0.46
MAPK13 O15264 1/20 0.46
ABL1 P00519 1/20 0.46
CYP1A2 P05177 1/20 0.46
CDK1 P06493 1/20 0.46
CYP3A4 P08684 1/20 0.46
FBP1 P09467 1/20 0.46
CYP2D6 P10635 1/20 0.46
MAPT P10636 1/20 0.46
CYP2C9 P11712 1/20 0.46
SRC P12931 1/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8241313 0.88 KDR (0.50) KDRACHEBACE1ATMEGFR
SCHEMBL4982411 0.71 ATM (0.56) ACHEBACE1ATMEGFRPIK3CA
SCHEMBL838162 0.71 SMO (0.51) KDM4ECYP1A2MAPTMAPK14
SCHEMBL9056703 0.69 EGFR (0.73) KDRACHEBACE1EGFRPDGFRB
SCHEMBL25340971 0.68 CYP11B2 (0.47) MAPK13MAPK12MAPK11MAPK14
Hydrochloric Acid SCHEMBL8652234 0.68 EGFR (0.74) KDRACHEBACE1EGFRERBB2
SCHEMBL837429 0.68 CYP11B1 (0.52) MAPTMAPK1
SCHEMBL29927676 0.68 ATM (0.69) KDRACHEBACE1ATMPIK3CA
SCHEMBL27075091 0.68 CYP11B2 (0.46) MAPK13MAPK12MAPK11MAPK14
SCHEMBL16109521 0.68 KIT (0.76) ACHEBACE1KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940819-A1 PHOSPHODIESTERASE 10 INHIBITORS Memory Pharmaceuticals Corporation (US) 2008-07-09 EP claimed
US-20070093515-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-04-26 US claimed
WO-2007022280-A1 PHOSPHODIESTERASE 10 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2007-02-22 WO claimed
EP-1940819-A1 PHOSPHODIESTERASE 10 INHIBITORS Memory Pharmaceuticals Corporation (US) 2008-07-09 EP disclosed
US-20070093515-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-04-26 US disclosed
US-20070093515-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-04-26 US disclosed
US-20070093515-A1 Phosphodiesterase 10 inhibitors AMGEN INC. 2007-04-26 US disclosed
WO-2007022280-A1 PHOSPHODIESTERASE 10 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093515-A1 Phosphodiesterase 10 inhibitors PDE7A, PDE12, PDE10A KDR 4600/4885ACHE 66/4885BACE1 707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.